GILD241206P101000
- 0.00
- 0.000.00%
Gilead Sciences Newsroom
Express News | Gilead : Leerink Partners Raises Target Price to $99 From $96
Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
BofA Securities Initiates Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $109
BofA Restarts Coverage of 11 Large-cap Biopharmas
Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3
Market Falls Wednesday, but Googles Chip Impresses | WST
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating
Express News | B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Citi Remains a Buy on Gilead Sciences (GILD)
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Gilead Sciences Analyst Ratings
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy
Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...
Longest Follow-Up Data Reported for Kite's Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits